abstract |
Disclosed are compositions comprising immunostimulatory oligonucleotides (CpG ODN) and FcR directed immunotherapeutic agents. Further disclosed are methods of using the composition to improve FcR-mediated antigen presentation, ADCC, and other FcR-mediated immune responses. |